Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

41. Proton Pump Inhibitors and Clostridium Difficile Infection

Proton Pump Inhibitors and Clostridium Difficile Infection Proton Pump Inhibitors and Clostridium Difficile Infection | Clinical Correlations Proton Pump Inhibitors and Clostridium Difficile Infection March 20, 2014 By Aaron Smith, MD Peer Reviewed First introduced in the late 1980s, proton pump inhibitors (PPIs) have revolutionized the treatment of gastric acid-related disorders and have been described as a miracle drug by patients and physicians alike. As is often the case with miracle drugs (...) , however, long-term use of PPIs has led to unforeseen adverse effects. Chief among the purported side effects of PPI use is an association with Clostridium difficile infection (CDI). CDI, an enterocolitis that leads to voluminous and potentially fatal diarrhea, .[1] Although [2], prevention of nosocomial CDI is critical to improving hospital safety, and therefore the potential association between CDI and PPI use has become a prominent, albeit controversial, issue. Some argue that PPIs are

Clinical Correlations2014

42. Histamine-2 Receptor Antagonists vs Proton Pump Inhibitors on Gastrointestinal Tract Hemorrhage and Infectious Complications in the Intensive Care Unit

Histamine-2 Receptor Antagonists vs Proton Pump Inhibitors on Gastrointestinal Tract Hemorrhage and Infectious Complications in the Intensive Care Unit 24535015 2014 04 08 2014 06 05 2014 07 24 2168-6114 174 4 2014 Apr JAMA internal medicine JAMA Intern Med Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit. 564-74 10.1001/jamainternmed.2013.14673 IMPORTANCE Histamine-2 receptor antagonists (...) (H2RAs) and proton pump inhibitors (PPIs) are commonly used to prevent gastrointestinal tract (GI) hemorrhage in critically ill patients. The stronger acid suppression of PPIs may reduce the rate of bleeding but enhance infectious complications, specifically pneumonia and Clostridium difficile infection (CDI). OBJECTIVE To evaluate the occurrence and risk factors for GI hemorrhage, pneumonia, and CDI in critically ill patients. DESIGN, SETTING, AND PARTICIPANTS A pharmacoepidemiological cohort study

EvidenceUpdates2014

43. [Notice on the reimbursement of proton pump inhibitors]

[Notice on the reimbursement of proton pump inhibitors] Avis sur le remboursement des inhibiteurs de la pompe à protons [Notice on the reimbursement of proton pump inhibitors] Avis sur le remboursement des inhibiteurs de la pompe à protons [Notice on the reimbursement of proton pump inhibitors] Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Avis sur le remboursement des inhibiteurs de la pompe à protons . [Notice on the reimbursement of proton pump inhibitors] Quebec: Institut national d'excellence en sante et en services sociaux (INESSS). ETMIS; 9(2). 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Humans; Proton Pump Inhibitors Language Published French Country of organisation Canada Province or state Quebec English summary An English language summary is available. Address for correspondence

Health Technology Assessment (HTA) Database.2014

44. Randomised controlled trial: For proton pump inhibitor-dependent gastro-oesophageal reflux, laparoscopic fundoplication is superior to medical therapy at 5?years of follow-up

Randomised controlled trial: For proton pump inhibitor-dependent gastro-oesophageal reflux, laparoscopic fundoplication is superior to medical therapy at 5?years of follow-up For proton pump inhibitor-dependent gastro-oesophageal reflux, laparoscopic fundoplication is superior to medical therapy at 5 years of follow-up | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here For proton pump inhibitor-dependent gastro-oesophageal reflux, laparoscopic fundoplication is superior to medical therapy at 5 years of follow-up Article Text Aetiology Randomised

Evidence-Based Medicine (Requires free registration)2014

45. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency.

Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. IMPORTANCE: Proton pump inhibitors (PPIs) and histamine 2 receptor antagonists (H2RAs) suppress the production of gastric acid and thus may lead to malabsorption of vitamin B12. However, few data exist regarding the associations between long-term exposure to these medications and vitamin B12 deficiency in large population-based studies. OBJECTIVE: To study the association between use of PPIs and H2RAs (...) electronic pharmacy, laboratory, and diagnostic databases. MAIN OUTCOMES AND MEASURES: Risk of vitamin B12 deficiency was estimated using odds ratios (ORs) from conditional logistic regression. RESULTS: Among patients with incident diagnoses of vitamin B12 deficiency, 3120 (12.0%) were dispensed a 2 or more years' supply of PPIs, 1087 (4.2%) were dispensed a 2 or more years' supply of H2RAs (without any PPI use), and 21,749 (83.8%) had not received prescriptions for either PPIs or H2RAs. Among patients

JAMA2013

46. Canadian Association of Gastroenterology position statement: Hip fracture and proton pump inhibitor therapy ? a 2013 update

Canadian Association of Gastroenterology position statement: Hip fracture and proton pump inhibitor therapy ? a 2013 update

CMA Infobase (Canada)2013

47. Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis

Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review (...) and meta-analysis Huang B, Huang Y, Li Y, Yao H, Jing X, Huang H, Li J CRD summary This review found that the use of proton-pump inhibitors with clopidogrel, for patients with coronary artery disease, was associated with increased risks of major adverse cardiac events and acute coronary syndrome. In general, the review was well conducted and the authors' conclusions are likely to be reliable. Authors' objectives To assess whether proton-pump inhibitors with clopidogrel increased the risks of major

DARE.2013

48. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis

Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis Giuliano C, Wilhelm SM, Kale-Pradhan PB CRD summary The review concluded that patients who received proton-pump inhibitors, particularly for shorter duration or at higher (...) doses, showed an association with community-acquired pneumonia. Large differences between studies and the potential for confounding factors limit the reliability of the authors’ conclusions. Authors' objectives To evaluate the association of proton-pump inhibitors with community-acquired pneumonia. Searching PubMed was searched from 1988 up to November 2011 for articles published in English. Search terms were reported. Reference lists of recent reviews and systematic reviews were handsearched. Study

DARE.2013

49. Cohort study: The association between proton pump inhibitor use and hip fracture cannot be explained by differences in dietary and lifestyle choices

Cohort study: The association between proton pump inhibitor use and hip fracture cannot be explained by differences in dietary and lifestyle choices The association between proton pump inhibitor use and hip fracture cannot be explained by differences in dietary and lifestyle choices | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here The association between proton pump inhibitor use and hip fracture cannot be explained by differences in dietary and lifestyle choices Article Text Aetiology Cohort study The association between proton pump inhibitor use

Evidence-Based Medicine (Requires free registration)2013

50. Esophageal reflux disease proton pump inhibitor therapy impact on sleep disturbance: a systematic review

Esophageal reflux disease proton pump inhibitor therapy impact on sleep disturbance: a systematic review Esophageal reflux disease proton pump inhibitor therapy impact on sleep disturbance: a systematic review Esophageal reflux disease proton pump inhibitor therapy impact on sleep disturbance: a systematic review Regenbogen E, Helkin A, Georgopoulos R, Vasu T, Shroyer AL CRD summary The authors concluded that, compared with placebo, proton-pump inhibitors improved some sleep disturbance-related (...) outcomes in patients with oesophageal reflux disease. This was a generally well-conducted review and the authors' conclusions reflected the findings. However, the limited combining of available evidence and the subjective outcome measures used suggest that the findings may not be reliable. Authors' objectives To assess the impact of proton-pump inhibitors on sleep disturbance-related outcomes in patients treated for gastro-oesophageal reflux disease. Searching PubMed, Web of Science, and The Cochrane

DARE.2013

51. Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome ? a systematic review

Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome ? a systematic review Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome – a systematic review Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome – a systematic review Jaspers Focks J, Brouwer MA, van Oijen MG, Lanas A, Bhatt DL, Verheugt FW CRD summary This review concluded (...) that the evidence for the clinical consequences of clopidogrel given with proton-pump inhibitors was controversial. Prospective clinical studies did not support any adverse effects. These conclusions reflect the evidence and seem reliable; the limitations of the evidence should be borne in mind. Authors' objectives To evaluate the impact of clopidogrel plus proton-pump inhibitors on platelet function and cardiovascular outcomes for patients with acute coronary syndrome or stents for stable coronary disease

DARE.2013

52. Cohort study: Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin

Cohort study: Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin Article Text Aetiology Cohort study Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin Ron Waksman 1

Evidence-Based Medicine (Requires free registration)2013

53. Are Proton-Pump Inhibitors Effective Treatment for Acute Undifferentiated Upper Gastrointestinal Bleeding?

Are Proton-Pump Inhibitors Effective Treatment for Acute Undifferentiated Upper Gastrointestinal Bleeding? DEFINE_ME_WA This site requires Cookies to be enabled to function. Please ensure Cookies are turned on and then re-visit the desired page.

Annals of Emergency Medicine Systematic Review Snapshots2013

54. Systematic review with meta-analysis: Proton pump inhibitor use may be associated with an increased risk of Clostridium difficile infection

Systematic review with meta-analysis: Proton pump inhibitor use may be associated with an increased risk of Clostridium difficile infection Proton pump inhibitor use may be associated with an increased risk of Clostridium difficile infection | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user (...) name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Proton pump inhibitor use may be associated with an increased risk of Clostridium difficile infection Article Text Aetiology Systematic review with meta-analysis Proton pump inhibitor use may be associated with an increased risk of Clostridium difficile infection

Evidence-Based Medicine (Requires free registration)2013

55. Cohort study: Proton pump inhibitors do not induce change in bone mineral density in a long-term observational study

Cohort study: Proton pump inhibitors do not induce change in bone mineral density in a long-term observational study Proton pump inhibitors do not induce change in bone mineral density in a long-term observational study | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Proton pump inhibitors do not induce change in bone mineral density in a long-term observational study Article Text Aetiology Cohort study Proton pump inhibitors do not induce change in bone mineral density in a long-term observational study Ryan D Madanick Statistics from Altmetric.com No Altmetric

Evidence-Based Medicine (Requires free registration)2013

56. Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists

Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists Barkun AN, Adam V, Martel M, Bardou M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of two types of drug to prevent stress ulcer bleeding in patients in the intensive care unit. The authors concluded that a proton pump inhibitor was more efficient than a histamine 2-receptor antagonist in preventing bleeding from a stress ulcer

NHS Economic Evaluation Database.2013

57. The Efficacy of Proton Pump Inhibitor Therapy for Treating Laryngopharyngeal Reflux: A Systematic Review

The Efficacy of Proton Pump Inhibitor Therapy for Treating Laryngopharyngeal Reflux: A Systematic Review "The Efficacy of Proton Pump Inhibitor Therapy for Treating Laryngophar" by Wendy Kellam < > > > > > Title Author Date of Award Summer 8-10-2013 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Laryngopharyngeal reflux (LPR) is the backflow of stomach contents into the throat. The current standard of care is to treat (...) patients with a proton pump inhibitor (PPI) twice daily for up to 6 months or longer. Two meta-analyses were completed in 2006 and found no evidence PPI therapy is better than placebo for chronic laryngitis. Since that time new tools have been created to measure outcomes in this field of research, the Reflux Finding Score (RFS) and Reflux Symptom Index (RSI). Using these standardized measures are researchers able to demonstrate PPI therapy is efficacious in the treatment of LPR? Method: An exhaustive

Pacific University EBM Capstone Project2013

58. [Description of the use of Proton Pump Inhibitors (PPIs) in adults covered by the public prescription drug insurance plan]

[Description of the use of Proton Pump Inhibitors (PPIs) in adults covered by the public prescription drug insurance plan] Portrait de l'usage des inhibiteurs de la pompe à protons (IPP) chez les adultes assurés par le régime public d'assurance médicaments [Description of the use of Proton Pump Inhibitors (PPIs) in adults covered by the public prescription drug insurance plan] Portrait de l'usage des inhibiteurs de la pompe à protons (IPP) chez les adultes assurés par le régime public (...) d'assurance médicaments [Description of the use of Proton Pump Inhibitors (PPIs) in adults covered by the public prescription drug insurance plan] L'Institut national d'excellence en sante et en services sociaux (INESSS) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation L'Institut national d'excellence en sante et en services sociaux (INESSS

Health Technology Assessment (HTA) Database.2012

59. Review: Proton-pump inhibitors are associated with increased risk for Clostridium difficile infection.

Review: Proton-pump inhibitors are associated with increased risk for Clostridium difficile infection. ACP Journal Club: review: proton-pump inhibitors are associated with increased risk for Clostridium difficile infection. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My (...) Bibliography Citation manager Format Create File 1 selected item: 22910967 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2012 Aug 21;157(4):JC2-13. doi: 10.7326/0003-4819-157-4-201208210-02013. ACP Journal Club: review: proton-pump inhibitors are associated with increased risk for Clostridium difficile infection. 1 . 1 Olive View-UCLA

Annals of Internal Medicine2012

60. Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From the Platelet Inhibition and Patient Outcomes Trial

Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From the Platelet Inhibition and Patient Outcomes Trial 22261200 2012 02 28 2012 04 19 2014 11 20 1524-4539 125 8 2012 Feb 28 Circulation Circulation Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. 978-86 10.1161/CIRCULATIONAHA.111.032912 The clinical significance (...) of the interaction between clopidogrel and proton pump inhibitors (PPIs) remains unclear. We examined the relationship between PPI use and 1-year cardiovascular events (cardiovascular death, myocardial infarction, or stroke) in patients with acute coronary syndrome randomized to clopidogrel or ticagrelor in a prespecified, nonrandomized subgroup analysis of the Platelet Inhibition and Patient Outcomes (PLATO) trial. The primary end point rates were higher for individuals on a PPI (n=6539) compared with those

EvidenceUpdates2012